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National surveys have documented 1- to 2-cm
deﬁcits in children’s heights for each 10-µg/dL
difference in blood lead levels (Ballew et al.
1999; Frisancho and Ryan 1991; Schwartz
et al. 1986), a finding replicated by several
clinical studies (Angle and Kuntzleman 1989;
Bithoney 1989; Lauwers et al. 1986; Routh
et al. 1979). Weight has been less consistently
associated with lead exposure (Ballew et al.
1999; Bithoney 1989; Johnson and Tenuta
1978; Kim et al. 1995; Schwartz et al. 1986).
The cross-sectional designs of most studies
limit inferences about the relationship of
blood lead to child growth. Longitudinal data
are required to discern growth effects during
and after adverse exposures (Prader et al.
1963; Tanner 1990). Observational studies
have shown that delays associated with lead
exposure are followed by catch-up growth
when blood levels decline (Shukla et al. 1989,
1991). Animal studies have suggested that
growth delay may be caused by decreased
caloric intake associated with anorexia, not by
direct effects of lead (Hammond and Succop
1995; Hammond et al. 1993).
If lead exposure indeed contributes to
height and weight deﬁcits, chelation to reduce
blood levels might ameliorate them. Studies of
chelation with ethylenediamine-tetraacetate
(EDTA) are not conclusive and are limited by
small sample sizes (Huseman et al. 1992;
Markowitz et al. 1990). We examined the
effect of succimer on height and weight
growth of children with moderate blood lead
levels during and after administration of suc-
cimer or placebo within a 34-month period in
the context of a randomized clinical trial. We
hypothesized that succimer would have a ben-
eficial effect on growth during but not after
treatment—that we would observe group dif-
ferences in growth rate during the period of
treatment, which was < 9 months for most
subjects.
Materials and Methods
The children were participants in the
Treatment of Lead-Exposed Children (TLC)
trial (TLC Trial Group 1998), a randomized,
multicenter, placebo-controlled, double-blind
clinical trial of succimer, an orally active drug
that forms water-soluble complexes with lead,
increasing its urinary excretion (Mann and
Travers 1991). The TLC trial tested the pri-
mary hypothesis that preschool children with
moderate blood lead levels treated with suc-
cimer would perform better than those receiv-
ing placebo on tests of cognitive development,
behavior, and neuropsychological function
administered 3 years after treatment (TLC
Trial Group 1998, 2000). Height and blood
pressure were secondary outcomes of the
trial. The research protocol was approved by
institutional review boards at the National
Institute of Environmental Health Sciences, the
Centers for Disease Control and Prevention
(CDC), the Harvard School of Public Health,
and the four clinical centers (Newark, NJ;
Baltimore, MD; Philadelphia, PA; and
Cincinnati/Columbus, OH).
Referral criteria included age of 12–33
months projected at randomization, blood
lead level between 20 and 44 µg/dL, no more
than two residences, and suitability for
psychometric tests in English or Spanish
(TLC Trial Group 1998). Exclusion criteria
were history of significant developmental
delay; renal, hepatic, or congenital heart dis-
ease; anemia not attributable to iron defi-
ciency; low birth weight; and prior chelation
therapy.
At the ﬁrst TLC visit, we measured height
and weight and obtained venous blood sam-
ples to measure blood lead level, ferritin,
hemoglobin, platelet and neutrophil counts,
red cell distribution width (RDW), and liver
enzymes. Children with hemoglobin levels
< 9.0 g/dL were excluded. Those with
increased RDW and hemoglobin between 9.0
and 10.0 g/dL were prescribed a 90-day
course of iron at 3 mg/kg/day, and enrollment
was delayed until iron deﬁciency was resolved.
We gave all families a month’s supply of a
chewable supplement providing 100% or
more of the recommended dietary allowances
(Food and Nutrition Board 1989) for chil-
dren for selected vitamins and minerals,
including iron, zinc, and copper, and 100 mg
calcium.
At the second TLC clinic visit 1 month
later, the child was enrolled in the study if
blood lead remained between 20 and 44 µg/dL.
Before therapy was initiated, homes were
cleaned to reduce lead dust exposure or families
were moved to lead-safe housing. We random-
ized 780 children: 396 to succimer and 384
to placebo. Treatment assignments were ran-
domized within strata of clinical center, six
categories of body surface area, blood lead
(≤ 25 µg/dL or > 25 µg/dL), and, in Newark
only, English or Spanish language testing (TLC
Trial Group 1998). Treatment with succimer
or placebo was started within 2 weeks of the
second qualifying blood lead. Treated children
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Growth deficits associated with lead exposure might be ameliorated by chelation. We examined
the effect of succimer on growth in 780 children 12–33 months old who had blood lead levels of
20–44 µg/dL and were randomized to receive up to three 26-day courses of succimer or placebo in
a multicenter, double-blind trial. The difference in changes in weight and height between suc-
cimer and placebo groups at 1–34 months was calculated by ﬁtting cubic splines. The difference
in height change in children on succimer compared with placebo was –0.27 cm [95% conﬁdence
interval (95% CI), –0.42 to –0.11] from baseline to 9 months, when 99% of children had com-
pleted treatment, and –0.43 cm (95% CI, –0.77 to –0.09) during 34 months of follow-up. Similar
differences in weight gain were not statistically signiﬁcant. Although succimer lowers blood lead in
moderately lead-poisoned children, it does not have a beneﬁcial effect on growth and may have an
adverse effect. Key words: blood lead levels, chelation, children, clinical trial, growth, succimer.
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http://dx.doi.org/ [Online 22 October 2003]were assigned to a dosing regimen providing
1,050 mg/m2/day of succimer for the first
7 days, and then 700 mg/m2/day from 8 to
26 days, a week longer than the regimen
described on the product label (Chemet;
McNeil Consumer Products, Fort Washington,
PA). We suspended vitamin–mineral supple-
ments during the treatment period.
Children could receive up to three courses
of succimer if blood lead was ≥ 15 µg/dL
42 days after initiating the first or second
round of treatment. The timing of this visit
was somewhat variable, conducted at a median
of 48 days (5–95% range, 41–101 days) for
the ﬁrst course and at a similar range for the
second course. Among children given suc-
cimer who completed the first round, 83%
required a second course; 83% of those com-
pleting a second round required a third
course. Children given placebo were assigned
to retreatment to match the frequency of
retreatment of those receiving succimer within
blocks used for initial randomization. At the
conclusion of treatment, vitamin–mineral sup-
plementation was resumed for the duration of
the study. Children returned for clinical exam-
ination and repeat measures of blood lead
level, height, and weight every 3 months dur-
ing the ﬁrst 2 years and at 4-month intervals
in the third year. Clinicians provided follow-
up care for post-treatment blood lead levels
according to CDC guidelines (CDC 1991).
Data collection. Questionnaires. Age and
sex were obtained by caregiver interview at
referral for eligibility. Birth weight, history of
disqualifying medical conditions, race/ethnicity,
medical insurance, and participation in federal
health and welfare programs were reported at
the first and second prerandomization clinic
visits.
Biochemical measures. The Nutritional
Biochemistry Branch of the CDC measured
blood lead levels using methods described by
Miller et al. (1987) and tested the evacuated
blood collection tubes for lead contamina-
tion. This CDC lab also measured ferritin;
hemoglobin was determined at local laborato-
ries (TLC Trial Group 1998).
Anthropometry. TLC staff obtained
heights and weights according to accepted
guidelines [Lohman et al. 1988; World
Health Organization (WHO) 1995] modiﬁed
for outpatient settings (Gortmaker et al.
1999). We measured weight on a balance
beam or digital scale recorded to the nearest
0.1 kg or ounce. Length and stature measures
were measured to the nearest 0.1 cm using
infant length boards or stadiometers, respec-
tively. Clinic equipment was calibrated
weekly or every 100 children using standard
weights and measuring rods.
The study protocols speciﬁed length meas-
ures on children < 24 months old and stature
at ≥ 24 months (Lohman et al. 1988; WHO
1995). We corrected heights for position,
converting supine to standing measures by
subtracting an age-independent constant
(Hamill et al. 1979; Mei et al. 1998). For chil-
dren with missing values for position, we
assumed that recumbent lengths were meas-
ured for children < 24 months old and stature
measured on older children. To estimate the
value of the difference due to position in the
TLC, we ﬁtted a child-speciﬁc growth curve
against age to the standing measurements for
297 children who had both supine and stand-
ing measurements and calculated deviations
from this curve for supine measurements for
each individual. This analysis yielded 824
deviations with the average value equal to
0.49 cm. All supine measures were subse-
quently adjusted to standing height by sub-
tracting 0.49 cm.
Statistical methods. We calculated treat-
ment- and time-speciﬁc mean blood lead lev-
els by locally weighted regression (Cleveland
and Devlin 1988) using S-Plus software
(Mathsoft, Seattle, WA) as described in
Chambers and Hastie (1993). Average pos-
trandomization blood lead level was calcu-
lated for each child by connecting the
visit-speciﬁc measurements of blood lead level
by straight lines and calculating the area
under the resulting curve divided by the
length of the interval.
We used cubic B-splines (Venables and
Riley 1997) to ﬁt individual growth curves to
each child’s repeated measurements. We
selected this analytic approach for two reasons.
First, the rates of height and weight growth of
children in this age group are nonlinear,
declining with age. Although the time scale in
this study was months since randomization,
not child age, we would have needed to control
for age with a quadratic rather than linear
function. Second, we hypothesized that suc-
cimer would protect growth during the period
of treatment but not after treatment. Thus, we
anticipated a nonlinear response across the
study period; for example, we hypothesized
catch-up growth in children receiving succimer
from baseline to 9 months, followed by a simi-
lar growth rate in the two groups from 10 to
34 months. We estimated the change in height
and change of weight at any given time after
treatment began by subtracting the ﬁtted val-
ues at initiation of treatment from the fitted
values of height and weight at that time point.
This procedure produced child-speciﬁc curves
showing height and weight changes from base-
line to 34 months of follow-up. For subjects
whose last measurement was earlier than
34 months, the curve was ﬁtted up to the time
of this measurement. Figure 1 shows an exam-
ple of a smooth curve ﬁtted to observed height
measurements for an individual child using
these methods. The goodness of ﬁt was excel-
lent; the mean R2 values for observed and ﬁtted
values over subjects were 0.98 for height and
0.97 for weight.
From the analysis of height growth, we
eliminated 2.7% of subjects with fewer than six
measurements, and an additional 2.7% with
missing baseline covariates from the adjusted
analysis. Ninety-four percent of children were
included in the covariate-adjusted analysis at
6 months, 92% at 24 months, and 88% at
34 months of follow-up. Corresponding num-
bers were similar for weight growth analyses.
We conducted analysis of covariance of change
in ﬁtted values for height and weight from ini-
tiation of treatment at multiple time points
from 1 to 34 months. We estimated the differ-
ence in height and weight change between the
children given succimer and those given
placebo, adjusting for baseline age, blood lead
level, ferritin and hemoglobin, sex, race/eth-
nicity (African-American vs. other), clinical
center and baseline Z-score for height or
weight (corresponding to the outcome of
interest). For baseline weights and heights, we
calculated age- and sex-speciﬁc Z-scores (Dean
et al. 1995), using the closest measure col-
lected within 1 month of randomization.
Because children with larger Z-scores would
be expected to grow faster independent of any
treatment effect, we estimated the magnitude
of the association of baseline height Z-score
with height change at 34 months. We
included reported birth weight in initial mod-
els but excluded it from ﬁnal analyses to maxi-
mize sample size for the covariance analyses.
Similar results were obtained in models that
included birth weight. S-Plus software
(Venables and Riley 1997) was used for the
robust analysis of covariance, following an
approach similar to that discussed by Ramsay
and Silverman (1997).
In response to reviewer comments and to
assess the robustness of the cubic spline analy-
sis, we also conducted a growth analysis
(Laird and Ware 1982), using age as the
metameter and time on study as a covariate.
We assumed that height (or weight) at a spe-
ciﬁc follow-up time is a function of subject’s
Children’s Health | Peterson et al.
234 VOLUME 112 | NUMBER 2 | February 2004 • Environmental Health Perspectives
Figure 1. Smooth curve fitted to observed height
data. A change of height Ch(t) at time t from the ini-
tiation of treatment is defined as the difference
between the ﬁtted value of height and ﬁtted height
value of height at the baseline: Ch(t) = h(t) – h(0).
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● ●current age, squared current age, race/ethnic-
ity (African American vs. other), sex, clinical
center, treatment group, and interaction of
treatment group with time from the initiation
of treatment. We also assumed random inter-
cepts and coefficients for age and the square
of age. The coefﬁcient of the interaction term
in this model represents the difference
between treatment groups in the average
growth velocity across the follow-up period.
This analysis was done using SAS PROC
MIXED (SAS Institute 1992).
Results
Baseline health and sociodemographic charac-
teristics of the children were balanced across
succimer and placebo groups (Tables 1 and 2).
Of these low-income, urban families, fewer
than 5% received no public assistance; about
three-quarters were enrolled in Medicaid, in
the Food Stamp Program, and in the Special
Supplemental Nutrition Program for Women,
Infants, and Children (TLC Trial Group
1998). At baseline, mean blood lead levels were
25.9 (SD = 4.8) µg/dL in children randomized
to receive placebo and 26.5 (SD = 5.4) µg/dL
in children randomized to receive succimer.
After 9 months of follow-up, 99% had
completed treatment. The 34-month trajecto-
ries of mean blood lead levels in the children
receiving placebo and succimer appear in
Figure 2. The largest estimated difference in
mean blood lead level, 11 µg/dL (0.5 µmol/L),
was seen 1 week after initiating the ﬁrst round
of treatment. Blood lead levels partially
rebounded after successive rounds, whereas
the mean blood lead levels of children given
placebo declined smoothly but slowly.
Averaged over time, the mean blood lead level
of succimer-treated children was 4.5 µg/dL
[95% conﬁdence interval (CI), 3.7–5.3 µg/dL]
lower than that of placebo children during the
6-month period after initiation of treatment,
and 2.7 µg/dL (95% CI, 1.9–3.5 µg/dL) lower
during the 12-month period after initiation of
treatment (TLC Trial Group 2000). From 12
to 34 months, mean blood lead levels did not
differ signiﬁcantly in children randomized to
succimer and placebo (Figure 2).
Succimer was associated with slower
growth in height and in weight in the first
34 months from randomization. Figure 3
shows the differences between groups in height
and weight changes from baseline to 34 months
with pointwise 95% CIs, estimated by ﬁtting
cubic splines. Differences between height
changes of succimer- and placebo-treated chil-
dren emerged in the ﬁrst 6–9 months, whereas
weight discrepancies increased gradually to
18 months. Table 3 displays numerical values
of the difference for selected times after the ini-
tiation of treatment. Mean differences in
height change [Ch(succimer) – Ch(placebo)]
were –0.27 cm (95% CI, –0.42 to –0.11 cm)
at 9 months and –0.43 cm (95% CI, –0.77 to
–0.09 cm) at 34 months, adjusted for covari-
ates. We examined whether the small and non-
signiﬁcant group difference in baseline height
inﬂuenced these effects. Using baseline height
Z-score as one of the covariates in the adjusted
model shown in Table 3, we found, as
expected, that children with higher Z-scores at
baseline grew faster than those with lower 
Z-scores during the study period. The magni-
tude of underlying group differences in growth
rate was quite small, however. For example,
an increase in baseline height Z-score by one
unit was associated with an additional height
change of 0.88 cm (95% CI, 0.71–1.05 cm) at
34 months. With the exceptionally small
group difference in baseline height Z-scores,
the magnitude of the corresponding adjust-
ment (0.88 cm/unit × 0.013 units = 0.01 cm)
was much smaller than the primary effect at
34 months (0.43 cm). Children given succimer
also appeared to gain less weight than did
placebo children during the study period,
although these adjusted differences were not
statistically significant: –0.02 kg (95% CI,
–0.10 to 0.05 kg) at 9 months and –0.12 kg
(95% CI, –0.35 to 0.10 kg) at 34 months of
follow-up.
In the analysis based on random-effects
models, the estimated height growth rate in
children receiving succimer was slower by
0.13 cm (95% CI, 0.00–0.26 cm) per year,
adjusted for covariates. Weight growth veloc-
ity was 0.10 kg (95% CI, –0.02 to 0.21 kg)
per year slower in children on succimer, com-
pared with those receiving placebo.
Discussion
In the TLC trial, succimer lowered blood lead
levels in children with moderate lead exposure
but did not have a beneﬁcial effect on growth
during or after active treatment. Blood lead
levels on average were 2.7/µg/dL lower among
children given succimer than among those
receiving placebo in the ﬁrst 12 months after
initiation of treatment (TLC Trial Group
2000). In this study, we found no signiﬁcant
group differences in blood lead levels from 12
to 34 months of follow-up. Children given
succimer had a –0.27-cm group difference in
height change from baseline to 9 months and
a –0.43-cm difference at 34 months. Height
change differences between treatment groups
at 9 and 34 months were not significantly
different, however, so we could not conclude
that group differences had widened after
treatment. Weight gain patterns were similar,
but group differences did not achieve statistical
signiﬁcance.
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Table 1. Baseline health status characteristics of randomized subjects by treatment group: TLC trial.
Placebo Succimer
No. Mean ± SD No. Mean ± SD
Age (months) 384 24.5 ± 5.5 396 24.4 ± 5.7
Blood lead (µg/dL) 384 25.9 ± 4.8 396 26.5 ± 5.4
Hemoglobin (g/dL) 384 11.7 ± 0.9 393 11.7 ± 0.9
Ferritin (µg/dL) 380 28.5 ± 19.6 393 28.1 ± 17.6
Birth weight (g) 361 3,169 ± 620 380 3,136 ± 551
Height (cm) 380 85.5 ± 5.7 388 85.3 ± 6.0
Height-for-age Z-score 380 –0.11 ± 1.01 388 –0.12 ± 1.01
Weight (kg) 374 12.3 ± 1.9 389 12.3 ± 2.0
Weight-for-age Z-score 374 –0.02 ± 1.18 389 0.01 ± 1.25
Body surface area (m2) 384 0.5 ± 0.1 396 0.5 ± 0.1
Figure 2. Mean blood lead levels and pointwise
95% CIs (shaded areas) at baseline and after the
initiation of treatment in children in succimer and
placebo groups. Rectangles in the upper left show
the mean and 95% CIs for the baseline values.
Means for the curves were calculated by locally
weighted regression.
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Table 2. Sociodemographic characteristics of randomized subjects by treatment group: TLC trial.
Placebo Succimer
No. (%) No. (%)
Females 165 (43.0) 178 (45.0)
African American 292 (76.0) 309 (78.0)
Study center
Baltimore 104 (27.1) 109 (27.5)
Newark 102 (26.6) 106 (26.8)
Philadelphia 83 (21.6) 82 (20.7)
Cincinnati/Columbus 95 (24.7) 99 (25.0)
Children’s Health | Succimer and growth in lead-exposed childrenFew studies have examined the relationship
of lead-chelating agents to postnatal growth.
Among infant rhesus monkeys with blood lead
levels comparable with those of children in the
TLC trial, two 19-day courses of succimer did
not signiﬁcantly affect weight, length, or head
circumference growth up to 2 years of age
(Lasky et al. 2001). EDTA had no effect on
height growth of lead-exposed children during
treatment (Markowitz et al. 1990), whereas
one case study reported partial catch-up after
therapy (Huseman et al. 1992).
The mechanism by which succimer would
have an adverse effect on growth is unknown.
Succimer has an unpleasant odor and taste
and could have affected children’s appetite
(Mann and Travers 1991) or the effort that
caregivers spent feeding the children. A vented
plastic cylinder of 200 mg of active drug
inside each bottle of placebo provided an obvi-
ous sulfur smell when opened, but placebo
tablets were odorless. More families reported
difficulty with administration of succimer
than with placebo (Rogan et al. 2001). Blood
lead levels were unlikely to explain group
differences in height change. During active
treatment, blood lead levels were always
lower in children on succimer, and rebounds
did not exceed baseline (20–44 µg/dL; TLC
Trial Group 2000). In the period from 10 to
34 months after treatment, blood lead levels
did not differ. Diuresis of minerals associated
with linear growth in children, such as zinc
(Brown et al. 2002), theoretically could have
contributed to differences in height change. A
modest 1.6-fold increase in zinc excretion was
documented in a 5-day clinical trial of suc-
cimer in children with high blood levels
(Graziano et al. 1992) but not among children
with moderate blood lead levels (Graziano
et al. 1988). The number and duration of
treatment courses were greater in the TLC
trial, but multivitamin and mineral supple-
ments including zinc were provided partici-
pants to prevent cation diuresis (TLC Trial
Group 1998).
The TLC study was a 3-year, randomized,
controlled trial of succimer, permitting exami-
nation of hypothesized effects during and
after treatment. Randomization within strata
ensured a relatively even distribution of sub-
ject characteristics across treatment arms.
Other study strengths included a high retention
rate and standardization of measurement tech-
niques and quality control of data collection
across the study sites. One limitation of the
study was our inability to adjust for unmea-
sured covariates (e.g., dietary intake), but ran-
domization provides the highest level of
protection against bias due to imbalances.
Information on time-dependent changes in
dietary intake or other unmeasured covariates
during active treatment might have provided
insight into mechanisms for observed effects,
but would not have changed group differ-
ences. We were unable to adjust for differ-
ences in growth rate before randomization,
but analyses suggested that the 0.2-cm group
difference in baseline heights would have a
negligible inﬂuence on the effect observed at
34 months. Inclusion of other covariates
known to be associated with growth velocity
or potential confounders of the lead–growth
relationship in the adjusted models slightly
increased the magnitude and precision of the
unadjusted effect estimates, particularly for
height. The growth curve analysis produced a
strikingly similar estimate of the difference in
growth rates between treatment groups,
demonstrating that the ﬁndings were robust.
The difference in growth rates between
treatment groups was marginally signiﬁcant in
all of the analyses we considered. Nevertheless,
results failed to support the hypothesis that
succimer treatment would have a beneficial
effect on growth in children with moderate
lead exposure, either during or after treatment,
and suggested that it may have adverse effects.
Primary results of the TLC trial also provided
no evidence that succimer improved scores on
tests of cognition, behavior, or neuropsycho-
logic function in children with moderate
blood lead levels (Rogan et al. 2001). The pos-
sibility of an adverse effect on growth seen in
the TLC trial strengthens the conclusion that
succimer, although effective in reducing blood
levels during active treatment, does not have
beneﬁcial effects on development in preschool
children with moderate lead exposure.
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Table 3. Mean (95% CI) differences in height and weight changes between succimer and placebo groups:
TLC trial.
Study Height (cm) Weight (kg)
month Unadjusted Adjusted Unadjusted Adjusted
6 –0.15 (–0.30 to –0.01) –0.20 (–0.32 to –0.09) –0.01 (–0.07 to 0.04) –0.02 (–0.07 to 0.04)
9 –0.20 (–0.40 to 0.00) –0.27 (–0.42 to –0.11) –0.02 (–0.10 to 0.06) –0.02 (–0.10 to 0.05)
12 –0.20 (–0.45 to 0.04) –0.28 (–0.46 to –0.10) –0.04 (–0.13 to 0.05) –0.05 (–0.14 to 0.03)
18 –0.23 (–0.55 to 0.09) –0.37 (–0.60 to –0.13) –0.08 (–0.21 to 0.05) –0.10 (–0.22 to 0.02)
24 –0.25 (–0.62 to 0.13) –0.36 (–0.64 to –0.09) –0.10 (–0.27 to 0.07) –0.14 (–0.29 to 0.02)
34 –0.33 (–0.79 to 0.12) –0.43 (–0.77 to –0.09) –0.07 (–0.32 to 0.17) –0.12 (–0.35 to 0.10)
Figure 3. Estimates of the difference in the means of changes in height (A) and weight (B) from baseline of
children in succimer and placebo groups. The upper and lower curves show pointwise 95% CIs for the esti-
mates, and the central curves show the estimated differences. A change of height Ch(t) and of weight Cw(t)
at time t from the initiation of treatment is deﬁned as the difference between the ﬁtted value and ﬁtted value
at the baseline: Ch(t) = h(t) – h(0) and Cw(t) = w(t) – w(0).
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